Yeah, financing is my main concern too.I'd hate to see more dilution like the last round.I hope that Al comes up with something that will help out us little guys.I'm also concerned about enrollment taking longer than anticipated and dragging the whole process out even longer. This question from the May earnings call still haunts me...

Kevin Tang - Tang Capital

So if I just take the outside of that, that's 18 months and I'm just wondering that the last 2 Phase III studies you ran, study 102 and 009 took 15 to 18 months just to enroll, not to complete the actual studies. So is it fair to say you're assuming that the enrollment period will be half of what it was in those studies?

Alfred Mann

Do you remember what they where?

Peter Richardson

I can't remember the exact enrollment time, but these are based on the assessments that have been done with our CRO and with some really careful diligence, in terms of how we can optimize the set up of this and these are the best estimates we have at the present time.

Hakan Edstrom

And if I remember it correctly, those studies also contained a much bigger patient number.

Kevin Tang - Tang Capital

I don't think they actually -- how many are you going to include in these studies?

Peter Richardson

150 completes per round.

Kevin Tang - Tang Capital

I think that's the same as the size of the prior 2, right?

http://seekingalpha.com/article/268906-mannkind-s-ceo-discusses-q1-2011-results-earnings-call-transcript?all=false&find=enrollment